Announced by Novo Nordisk on May 2, 2025, the investigational oral formulation of semaglutide is targeted for chronic weight management in patients with obesity or overweight and 1 comorbid condition and to reduce the risk of major adverse cardiovascular events (MACE) in those with overweight or obesity and established cardiovascular disease
As body mass reduces, some patients may notice a decrease in skin firmness or changes in texture
These might include dietary changes associated with weight loss, stress related to lifestyle modifications, concurrent medications, underlying mental health conditions, or other medical issues
The results are striking because the combination of these two drugs produces improvements in body composition we have never seen before in [] Past Due for Studying Maintenance Therapy in Obesity March 7, 2026 Health & Obesity, Scientific Meetings & Publications Neglect is a strong word
131 As we age, protein synthesis becomes imbalanced and is regulated by the mTOR pathway